Christopher Kenney

Chief Tech/Sci/R&D Officer at XENON PHARMACEUTICALS INC.

Net worth: - $ as of 2024-04-29

Health Technology

Christopher Kenney active positions

Companies	Position	Start	End
XENON PHARMACEUTICALS INC.	Chief Tech/Sci/R&D Officer	2021-08-22	-

Companies	Position	Start	End
Cadent Therapeutics, Inc. Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA.	Chief Tech/Sci/R&D Officer	2018-12-31	2020-11-30
ACORDA THERAPEUTICS, INC.	Chief Tech/Sci/R&D Officer	2015-12-31	2018-12-31
Biotie Therapies, Inc.	Chief Tech/Sci/R&D Officer	2012-12-31	2015-12-31

International

United States	4
Canada	2

Operational

Chief Tech/Sci/R&D Officer

Sectoral

Health Technology

Positions held

Active

Inactive

Listed companies

Private companies

Listed companies	2
XENON PHARMACEUTICALS INC.	Health Technology
ACORDA THERAPEUTICS, INC.	Health Technology

Private companies	2
Cadent Therapeutics, Inc. Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA.	Health Technology
Biotie Therapies, Inc.

Private companies

Health Technology

Biotie Therapies, Inc.